lnflammation in facioscapulohumeral muscular dystrophy

lnflammation in facioscapulohumeral muscular dystrophy - lnflammation in FSHD

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON46560

Enrollment

Registered

2018-04-25

Start date

2018-06-19

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

muscular dystrofy

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: -18-65 year old -Genetically confirmed FSHD1

Exclusion criteria

Exclusion criteria: - Age 65 years old - Diabetes mellitus - Chronic obstructive pulmonary disease - Current malignancy - Current treatment with chemotherapy and/or radiation therapy - Current use of corticosteroids - Current use of statines

Design outcomes

Primary

Measure	Time frame
We expect to better understand if and which role inflammation plays in the disease pathogenesis by evaluating the following outcomes: percentage and features of PBMC, cytokine profiling and gene expression both in FSHD1 patients and in healthy controls. Moreover, disease severity of FSHD patients will be assessed using a clinical severity score (Ricci-score).	—

Secondary

Measure	Time frame
Not applicable.	—

Countries

Netherlands

Outcome results